301 related articles for article (PubMed ID: 34447382)
1.
Petruccioli E; Petrone L; Chiacchio T; Farroni C; Cuzzi G; Navarra A; Vanini V; Massafra U; Lo Pizzo M; Guggino G; Caccamo N; Cantini F; Palmieri F; Goletti D
Front Immunol; 2021; 12():716857. PubMed ID: 34447382
[TBL] [Abstract][Full Text] [Related]
2. Study of CD27 and CCR4 Markers on Specific CD4
Latorre I; Fernández-Sanmartín MA; Muriel-Moreno B; Villar-Hernández R; Vila S; Souza-Galvão ML; Stojanovic Z; Jiménez-Fuentes MÁ; Centeno C; Ruiz-Manzano J; Millet JP; Molina-Pinargote I; González-Díaz YD; Lacoma A; Luque-Chacón L; Sabriá J; Prat C; Domínguez J
Front Immunol; 2018; 9():3094. PubMed ID: 30687314
[TBL] [Abstract][Full Text] [Related]
3. Impact of antiretroviral and tuberculosis therapies on CD4
Chiacchio T; Petruccioli E; Vanini V; Cuzzi G; La Manna MP; Orlando V; Pinnetti C; Sampaolesi A; Antinori A; Caccamo N; Goletti D
Immunol Lett; 2018 Jun; 198():33-43. PubMed ID: 29635002
[TBL] [Abstract][Full Text] [Related]
4. Modulation of CD4 and CD8 response to QuantiFERON-TB Plus in patients with active tuberculosis and latent tuberculosis infection followed over time during treatment.
Chiacchio T; Petruccioli E; Pepponi I; Vanini V; Gualano G; Cirillo D; Palmieri F; Ippolito G; Goletti D
Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S141-S142. PubMed ID: 28043513
[TBL] [Abstract][Full Text] [Related]
5. Immune profiling of Mycobacterium tuberculosis-specific T cells in recent and remote infection.
Mpande CAM; Rozot V; Mosito B; Musvosvi M; Dintwe OB; Bilek N; Hatherill M; Scriba TJ; Nemes E;
EBioMedicine; 2021 Feb; 64():103233. PubMed ID: 33610126
[TBL] [Abstract][Full Text] [Related]
6. Identification of Recent Tuberculosis Exposure Using QuantiFERON-TB Gold Plus, a Multicenter Study.
Pérez-Recio S; Pallarès N; Grijota-Camino MD; Sánchez-Montalvá A; Barcia L; Campos-Gutiérrez S; Pomar V; Rabuñal-Rey R; Balcells ME; Gazel D; Montiel N; Vicente D; Goić-Barišić I; Schön T; Paues J; Mareković I; Cacho-Calvo J; Barac A; Goletti D; García-Gasalla M; Barcala JM; Tórtola MT; Anibarro L; Suárez-Toste I; Moga E; Gude-Gonzalez MJ; Naves R; Karslıgil T; Martin-Peñaranda T; Stevanovic G; Trigo M; Rubio V; Karaoğlan İ; Bayram N; Alcaide F; Tebé C; Santin M;
Microbiol Spectr; 2021 Dec; 9(3):e0097221. PubMed ID: 34756079
[TBL] [Abstract][Full Text] [Related]
7. Lymphocyte subset analysis in QuantiFERON-TB Gold Plus and T-Spot.TB for latent tuberculosis infection in rheumatoid arthritis.
Igari H; Ishikawa S; Nakazawa T; Oya Y; Futami H; Tsuyuzaki M; Suzuki K; Matsumura R
J Infect Chemother; 2018 Feb; 24(2):110-116. PubMed ID: 29054459
[TBL] [Abstract][Full Text] [Related]
8. Functional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis.
Prezzemolo T; Guggino G; La Manna MP; Di Liberto D; Dieli F; Caccamo N
Front Immunol; 2014; 5():180. PubMed ID: 24795723
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of whole-blood interferon-γ and flow cytometry assays for detecting post-treatment immune responses in patients with active tuberculosis.
Kim CH; Choi KJ; Yoo SS; Lee SY; Won DI; Lim JO; Cha SI; Park JY; Lee J
Cytometry B Clin Cytom; 2014 Jul; 86(4):236-43. PubMed ID: 23959689
[TBL] [Abstract][Full Text] [Related]
10. First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus.
Petruccioli E; Chiacchio T; Pepponi I; Vanini V; Urso R; Cuzzi G; Barcellini L; Cirillo DM; Palmieri F; Ippolito G; Goletti D
J Infect; 2016 Dec; 73(6):588-597. PubMed ID: 27717779
[TBL] [Abstract][Full Text] [Related]
11. A CD4+CD161+ T-Cell Subset Present in Unexposed Humans, Not Tb Patients, Are Fast Acting Cells That Inhibit the Growth of Intracellular Mycobacteria Involving CD161 Pathway, Perforin, and IFN-γ/Autophagy.
Yang R; Peng Y; Pi J; Liu Y; Yang E; Shen X; Yao L; Shen L; Modlin RL; Shen H; Sha W; Chen ZW
Front Immunol; 2021; 12():599641. PubMed ID: 33732233
[TBL] [Abstract][Full Text] [Related]
12. Increased Frequency of Memory CD4+ T-Cell Responses in Individuals With Previously Treated Extrapulmonary Tuberculosis.
Barreto-Duarte B; Sterling TR; Fiske CT; Almeida A; Nochowicz CH; Smith RM; Barnett L; Warren C; Blackman A; Lapa E Silva JR; Andrade BB; Kalams SA
Front Immunol; 2020; 11():605338. PubMed ID: 33391271
[TBL] [Abstract][Full Text] [Related]
13. Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases.
Chiacchio T; Petruccioli E; Vanini V; Cuzzi G; Massafra U; Baldi G; Navarra A; Scrivo R; Mastroianni C; Sauzullo I; Esposito C; Palmieri F; Cantini F; Goletti D
J Infect; 2019 Jul; 79(1):15-23. PubMed ID: 30981891
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the CD4 and CD8 T-cell response in the QuantiFERON-TB Gold Plus kit.
Petruccioli E; Chiacchio T; Pepponi I; Vanini V; Urso R; Cuzzi G; Barcellini L; Palmieri F; Cirillo DM; Ippolito G; Goletti D
Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S25-S26. PubMed ID: 28043588
[TBL] [Abstract][Full Text] [Related]
15. Alternative biomarkers of tuberculosis infection in patients with immune-mediated inflammatory diseases.
Petruccioli E; Petrone L; Najafi-Fard S; Navarra A; Vanini V; Cuzzi G; Cantini F; Gualano G; Palmieri F; Goletti D
Front Med (Lausanne); 2023; 10():1271632. PubMed ID: 38076244
[TBL] [Abstract][Full Text] [Related]
16. Anti-tuberculosis chemotherapy alters TNFR2 expression on CD4+ lymphocytes in both drug-sensitive and -resistant tuberculosis: however, only drug-resistant tuberculosis maintains a pro-inflammatory profile after a long time.
Téllez-Navarrete NA; Ramon-Luing LA; Muñoz-Torrico M; Preciado-García M; Medina-Quero K; Hernandez-Pando R; Chavez-Galan L
Mol Med; 2021 Jul; 27(1):76. PubMed ID: 34261449
[TBL] [Abstract][Full Text] [Related]
17. Distinct effector memory CD4+ T cell signatures in latent Mycobacterium tuberculosis infection, BCG vaccination and clinically resolved tuberculosis.
Adekambi T; Ibegbu CC; Kalokhe AS; Yu T; Ray SM; Rengarajan J
PLoS One; 2012; 7(4):e36046. PubMed ID: 22545156
[TBL] [Abstract][Full Text] [Related]
18. Characterization of CD4/CD8+ αβ and Vγ2Vδ2+ T cells in HIV-negative individuals with different Mycobacterium tuberculosis infection statuses.
Gao Y; Zhang S; Ou Q; Shen L; Wang S; Wu J; Weng X; Chen ZW; Zhang W; Shao L
Hum Immunol; 2015 Nov; 76(11):801-7. PubMed ID: 26429305
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometry-based method using diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease.
Dolezalova K; Hadlova P; Ibrahimova M; Golias J; Baca L; Kopecka E; Sukholytka M; Koziar Vasakova M
Tuberculosis (Edinb); 2024 Jul; 147():102518. PubMed ID: 38739968
[TBL] [Abstract][Full Text] [Related]
20.
Mpande CAM; Steigler P; Lloyd T; Rozot V; Mosito B; Schreuder C; Reid TD; Bilek N; Ruhwald M; Andrews JR; Hatherill M; Little F; Scriba TJ; Nemes E
Front Immunol; 2021; 12():712480. PubMed ID: 34526988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
